利拉鲁肽对2型糖尿病患者血浆丝氨酸蛋白酶抑制剂水平的影响

Effects of Liraglutide on plasma Vaspin level in patients with type 2 diabetes mellitus

目的探讨胰高糖素样肽-1(GLP-1)类似物利拉鲁肽(Liraglutide)对2型糖尿病(T2DM)患者血浆丝氨酸蛋白酶抑制剂(Vaspin)水平的影响。方法采用酶联免疫法测定T2DM患者及正常人Vaspin水平,分析血浆Vaspin水平与体重指数(BMI)、腰臀比(WHR)、胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-IS)、游离脂肪酸(FFA)等的关系,观察利拉鲁肽治疗前后T2DM患者血浆Vaspin水平变化。结果 T2DM患者血浆Vaspin水平显著高于正常人(P<0.05)。血浆Vaspin水平与空腹血糖(FPG)及糖化血红蛋白(HbA1c)呈明显正相关(r=0.35,P<0.01和r=0.25,P<0.05),而与DBP呈明显负相关(r=-0.25,P<0.05),FPG、WHR分别是影响血浆Vaspin水平的独立相关因素。T2DM患者经利拉鲁肽治疗后,体重、BMI、WHR、FPG、餐后2小时血糖(2hPG)、HbA1c均显著降低(P<0.01),而HOMA-IS则显著增高(P<0.01),空腹血浆Vaspin也显著增高(P<0.05)。结论利拉鲁肽能有效改善T2DM患者糖脂代谢和胰岛素敏感性,增强胰岛β细胞功能,同时升高血浆Vaspin水平。

Objective To investigate the effects of long-acting human glucagonlike peptide-1（GLP-1） analog Liraglutide on plasma Vaspin level in patients with type 2 diabetes mellitus（T2DM）.Methods Plasma Vaspin level was measured by ELISA in patients with T2DM and normal controls（NGT）.The relationship between plasma Vaspin levels and BMI,WHR,HOMA-IR,HOMA-IS,FFA were also analyzed.After Liraglutide treatment,plasma Vaspin levels was observed in patients with T2DM.Results T2DM group had significantly higher plasma Vaspin levels than that of NGT group（（0.73±0.32） vs.（0.54±0.22） μg/L,P0.05）.Plasma Vaspin level was correlated positively with FPG,HbA1c（r=0.35,P0.01 and r=0.25,P0.05） and negatively with DBP（r=-0.25,P0.05）.FPG and WHR were independently associated with plasma Vaspin level.After Liraglutide treatment,body weight,WHR,BMI,2 h PG,FPG and HbA1c were significantly decreased（all P0.01）,and HOMA-IS level was significantly increased（P0.01）in T2DM patients.Interestingly,fasting plasma Vaspin level was also significantly increased on post-treatment with Liraglutide（（0.73±0.32） vs.（0.92±0.38） μg/L,P0.05）.Conclusions Liraglutide can remarkably improve glucose and lipid metabolism,insulin resistance,as well as pancreatic β-cell function and elevate plasma Vaspin level.